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Abstract 
Aims 
The aims of this thesis were to investigate herd level risk factors for heifer clinical 
mastitis and to test the efficacy of a pre-calving intervention on prevalence of post-
calving IMI, incidence of clinical mastitis and somatic cell count (SCC) in heifers. 
Materials and methods 
A prospective survey ( chapter 3) was used to collect data concerning farmers ' 
management practices for rearing heifers and mastitis management. A proportion of 
herd-owners (n=250) subsequently provided data on the clinical mastitis cases in their 
herd occurring in the first 120 days of the subsequent lactation. 
A pilot quarter level intervention study (n=I 000 quarters; chapter 4) investigated the 
effect of pre-calving infusion of a teat sealant. Glands were randomly assigned to one 
of 4 treatment groups (no treatment; mammary gland secretion collection; infusion of 
a teat sealant; or sample collection with infusion of teat sealant) to identify the risk of 
each of these treatments on post-calving IMI and clinical mastitis. 
A heifer level intervention study (n= l 000 heifers; chapter 5, 6) investigated the pre-
calving use of teat sealant infused into all four quarters and/or treatment with the 
injectable antibiotic tylosin . Analysis was undertaken at quarter level ( chapter 5) and 
heifer level (including SCC data; chapter 6). 
Results 
The survey identified that the cumulative incidence of heifers with clinical mastitis 
was higher in herds with a higher per cow milk production, with more cows milked 
per person, in herds with a higher stocking rate, and in herds with a higher cumulative 
incidence of clinical mastitis in their multiparous cows. The cumulative incidence of 
heifers in a herd with clinical mastitis was lower in herds that managed the lactating 
cows in multiple groups. 
The pilot study found that the presence of an IMI pre-calving increased the risk of an 
IMI post-calving and the incidence of clinical mastitis, relative to no IMI pre-calving. 
Infusion of the teat sealant reduced the risk of post-calving IMI due to Streptococcus 
uberis and the incidence of clinical mastitis. Sampling the glands pre-calving had no 
effect on post-calving IMI or on incidence of clinical mastitis. 
The large-scale intervention study found that neither infusion of a teat sealant nor 
treatment with the injectable antibiotic increased the risk of cure of pre-calving IMI. 
Infusion of the teat sealant reduced the risk of quarter level new IMI. At both quarter 
and heifer level teat sealant reduced the risk of the prevalence of post-calving IMI, 
incidence of clinical mastitis. At heifer level the SCC was decreased throughout 
lactation following the use of a teat sealant. Tylosin had no effect on prevalence of 
IMI, incidence neither of clinical mastitis nor on SCC. 
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Conclusions 
It was concluded that the risk of heifer clinical mastitis was associated with a number 
of herd level management factors and that further studies are required to elucidate the 
mechanisms behind these associations. Hence, it may be possible to reduce the 
incidence of clinical mastitis in heifers by modification of herd level management 
practices. Intervention with an intramammary teat sealant pre-calving decreased the 
incidence of new infections over this high-risk peripartum period, and may provide a 
useful tool for reducing the risk of subclinical and clinical mastitis in heifers. 
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